Cytokinetics pharmaceuticals news
WebNov 4, 2024 · Cytokinetics Market Cap $3B Today's Change (-0.80%) -$0.27 Current Price $33.36 Price as of March 24, 2024, 4:00 p.m. ET CYTK earnings call for the period ending September 30, 2024. Image source:... WebSTOCK QUOTE Cytokinetics, Inc. INVESTORS & MEDIA STOCK QUOTE Stock Quote Stock Chart Historical Price Lookup Data Provided by Refinitiv. Minimum 15 minutes delayed. Mar 31 2024 11:06 pm EDT Data Provided by Refinitiv. Minimum 15 minutes delayed. STOCK CHART SHAREHOLDER TOOLS
Cytokinetics pharmaceuticals news
Did you know?
WebNov 3, 2024 · Cytokinetics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $2.52 million for the quarter ended September 2024, … WebJan 11, 2024 · ClinicalTrials.gov Identifier: NCT05186818 Recruitment Status : Recruiting First Posted : January 11, 2024 Last Update Posted : March 13, 2024 See Contacts and Locations View this study on Beta.ClinicalTrials.gov Sponsor: Cytokinetics Collaborator: Ji Xing Pharmaceuticals (Shanghai) Co., Ltd. Information provided by (Responsible Party):
WebAug 2, 2024 · About Cytokinetics. Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and ... WebMar 1, 2024 · Cytokinetics Inc said on Tuesday the U.S health regulator declined to approve its oral drug for a type of heart failure, citing lack of sufficient data to show the …
WebFeb 27, 2024 · Reata Pharmaceuticals is expecting a Feb. 28 decision for its Friedreich's ataxia hopeful, omaveloxolone. The drug activates Nrf2, a transcription factor that helps … WebDec 9, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised.
Web2 days ago · Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of ...
WebJan 7, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Investors & Media Cytokinetics’ unparalleled expertise … increase bitrate of videoincrease by 120%WebMar 27, 2024 · PRESS RELEASES Cytokinetics, Inc. INVESTORS & MEDIA 2024 Press Releases Webcast 22nd Annual Needham Virtual Healthcare Conference Apr 17, 2024 10:00 AM EDT Keyword Search Press Release Archive 1998-2005 Year 2024 Apr 11 2024 5:00 pm EDT Data Provided by Refinitiv. Minimum 15 minutes delayed. STOCK CHART increase by 6 timesWebApr 11, 2024 · Cytokinetics (NASDAQ:CYTK) has a market capitalization of $3.48 billion and generates $94.59 million in revenue each year. The biopharmaceutical company … increase by 30 percentWebApr 10, 2024 · It has been a rough year so far for late-stage biopharmaceutical company, Cytokinetics, Incorporated CYTK. Shares of the company have moved down 20.5% compared with the industry’s decline of 4.7%. increase by a foldWebApr 10, 2024 · Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. About the company Rewards Revenue is forecast to grow 46.65% per year Risk Analysis Negative shareholders equity increase by 80%WebNov 30, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. increase by 50% means